Tag: Endologix

Endologix Reports Five-Year Data of the LEOPARD Trial at 2022 Vascular InterVentional Advances (VIVA) Conference

The LEOPARD (Looking at EVAR Outcomes by Primary Analysis of Randomized Data) trial is the first randomized controlled trial (RCT) comparing the outcomes of endovascular aneurysm repair (EVAR) using commercially available devices in a real-world population. IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device […]

ELEVATE IDE Study highlights the Safety and Effectiveness of the ALTO® Abdominal Stent Graft System in One-year Results; Data to Be Presented at 2022 VEITHsymposium

The Endologix ALTO Stent Graft System treats abdominal aortic aneurysms (AAA) with a success rate of 96.7% at 12 months as observed in ELEVATE IDE Study IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving […]

Endologix Submits Premarket Approval (PMA) Application to FDA for the DETOURTM System.

 FDA to Review First-of-Its-Kind Percutaneous Femoropopliteal Bypass System IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ lives by providing disruptive therapies for the interventional treatment of vascular disease, today announced the submission of […]

Endologix Reports 12 Month Data from DETOUR 2 Clinical Trial at 2022 Vascular Annual Meeting

The DETOUR 2 study is a prospective, single-arm, international, multi-center clinical evaluation of the novel DETOUR™ System for fully percutaneous femoropopliteal bypass procedures. IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ lives with […]

Dr. Stephen J. Hoenig Completes First-of-its-Kind Procedure at The Vascular Care Group, Leominster

Minimally invasive procedure decreases recovery time and demonstrates new opportunities in outpatient care LEOMINSTER, Mass.–(BUSINESS WIRE)–The Vascular Care Group (TVCG), a state-of-the art practice committed to the prevention, diagnosis and treatment of vascular disease, today announced Stephen J. Hoenig M.D. successfully […]

Endologix LLC Receives FDA Breakthrough Device Designation for ChEVAS™ System

Investigational EVAS System Designed for Patients with Complex Abdominal Aortic Aneurysm IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a leader in the treatment of vascular disease, today announced the company’s ChEVAS™ (Chimney EndoVascular Aneurysm Sealing) System has been granted a Breakthrough Device Designation […]